105,609 Shares in Theravance Biopharma, Inc. (NASDAQ:TBPH) Bought by Algert Global LLC

Algert Global LLC purchased a new position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 105,609 shares of the biopharmaceutical company's stock, valued at approximately $851,000. Algert Global LLC owned approximately 0.22% of Theravance Biopharma as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of TBPH. Kennedy Capital Management LLC lifted its holdings in Theravance Biopharma by 3.7% in the 1st quarter. Kennedy Capital Management LLC now owns 38,202 shares of the biopharmaceutical company's stock worth $343,000 after purchasing an additional 1,359 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Theravance Biopharma by 7.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company's stock worth $444,000 after purchasing an additional 3,532 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Theravance Biopharma by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 3,696 shares in the last quarter. American Century Companies Inc. lifted its holdings in Theravance Biopharma by 11.7% in the 2nd quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company's stock worth $489,000 after purchasing an additional 6,026 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new position in Theravance Biopharma in the 2nd quarter worth approximately $108,000. 99.10% of the stock is owned by institutional investors.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the company's stock in a transaction on Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now owns 322,743 shares of the company's stock, valued at $2,904,687. This represents a 1.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Leerink Partners cut Theravance Biopharma from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $15.00 to $10.00 in a report on Tuesday, August 6th. TD Cowen reduced their price objective on Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating on the stock in a research note on Tuesday, August 6th. Leerink Partnrs downgraded Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 6th. StockNews.com downgraded Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Saturday, August 10th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Monday, September 16th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $13.75.

Theravance Biopharma Trading Down 1.8 %

Shares of NASDAQ TBPH traded down $0.17 during trading hours on Friday, hitting $9.25. 91,398 shares of the company traded hands, compared to its average volume of 341,571. The stock has a market capitalization of $454.86 million, a price-to-earnings ratio of -9.16 and a beta of 0.25. The company's 50 day moving average price is $8.69 and its 200 day moving average price is $8.71. Theravance Biopharma, Inc. has a 12 month low of $7.44 and a 12 month high of $11.71.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The company had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. During the same period in the prior year, the firm posted ($0.17) EPS. Equities analysts anticipate that Theravance Biopharma, Inc. will post -1.06 EPS for the current year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.